Related Experiment Video
Updated: Dec 9, 2025

Cholesterol Efflux Assay
Published on: March 6, 2012
Increased ABCA1 (ATP-Binding Cassette Transporter A1)-Specific Cholesterol Efflux Capacity in Schizophrenia
Céline Luquain-Costaz1, Maaike Kockx2, Malcolm Anastasius2
1INSERM U1060, Carmen laboratory, INSA de Lyon, Villeurbanne, France (C.L.-C.).
Insights
Patients with schizophrenia show altered cholesterol transport, with higher HDL cholesterol efflux capacity despite lower HDL levels. This suggests a complex cardiovascular risk profile in schizophrenia, emphasizing atherogenic lipoprotein reduction.
Area of Science:
- Cardiovascular Disease Research
- Metabolic Disorders
- Neuropsychiatric Disorders
Background:
- Schizophrenia is linked to increased cardiovascular mortality and dyslipidemia, including low high-density lipoprotein cholesterol (HDL-C).
- High-density lipoprotein (HDL) cholesterol efflux capacity (CEC) is a key measure of HDL function and a predictor of cardiovascular risk.
- The impact of schizophrenia on HDL function, specifically CEC, remains largely unknown.
Purpose of the Study:
- To investigate HDL cholesterol efflux capacity (CEC) in patients with schizophrenia compared to healthy controls.
- To examine the relationship between CEC, lipoprotein subclasses, and clinical parameters in schizophrenia.
Main Methods:
- Measured basal, ATP-binding cassette transporter A1 (ABCA1)-dependent, and ABCG1-dependent CEC in 120 patients with schizophrenia and 51 healthy controls.
- Utilized nuclear magnetic resonance (NMR) analysis for lipoprotein subclass profiling.
- Correlated CEC findings with lipid profiles and apolipoprotein concentrations.
Main Results:
- Patients with schizophrenia exhibited lower HDL-C and apolipoprotein A-I but higher triglycerides and atherogenic lipoproteins.
- Despite lower HDL-C, basal and ABCA1-dependent CEC were significantly higher in patients with schizophrenia.
- ABCA1-specific efflux correlated with small HDL particle abundance in schizophrenia patients.
Conclusions:
- Schizophrenia is associated with enhanced ABCA1-mediated cholesterol efflux capacity, despite dyslipidemia and reduced large HDL particles.
- Preventative cardiovascular strategies in schizophrenia should prioritize reducing atherogenic lipoproteins over solely increasing CEC.
Objective:
Patients with schizophrenia have increased long-term mortality attributable to cardiovascular disease and commonly demonstrate features of mixed dyslipidemia with low HDL-C (high-density lipoprotein cholesterol). The removal of cholesterol from cells by HDL via specific ATP-binding cholesterol transporters is a major functional property of HDL, and its measurement as cholesterol efflux capacity (CEC) can predict cardiovascular risk. Whether HDL function is impaired in patients with schizophrenia is unknown. Approach and Results: We measured basal and ABCA1 (ATP-binding cassette transporter A1)- and ABCG1 (ATP-binding cassette transporter G1)-dependent CEC, comparing patients with schizophrenia with age- and sex-matched healthy controls, and related our findings to nuclear magnetic resonance analysis of lipoprotein subclasses. Total plasma cholesterol and LDL-C (low-density lipoprotein cholesterol) were comparable between healthy controls (n=51) and patients (n=120), but patients with schizophrenia had increased total plasma triglyceride, low HDL-C and apo (apolipoprotein) A-I concentrations. Nuclear magnetic resonance analysis indicated a marked (15-fold) increase in large triglyceride-rich lipoprotein particle concentration, increased small dense LDL particles, and fewer large HDL particles. Despite lower HDL-C concentration, basal CEC was 13.7±1.6% higher, ABCA1-specific efflux was 35.9±1.6% higher, and ABCG1 efflux not different, in patients versus controls. In patients with schizophrenia, ABCA1-specific efflux correlated with the abundance of small 7.8 nm HDL particles but not with serum plasminogen or triglyceride levels.
Conclusions:
Patients with schizophrenia have increased concentrations of atherogenic apoB-containing lipoproteins, decreased concentrations of large HDL particles, but enhanced ABCA1-mediated CEC. In this population, preventative strategies should focus on reducing atherogenic lipoproteins rather than increasing CEC.
Related Concept Videos
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Psychological and Sociocultural Causes of Schizophrenia
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...

